89
(Reuters) -Swiss drugmaker Novartis on Sunday said it agreed to acquire Avidity Biosciences for $12 billion. (Reporting by Angela Christy in Bengaluru)
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
